이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Travere Therapeutics 과거 수익 실적

과거 기준 확인 0/6

Travere Therapeutics의 수입은 연평균 -26.3%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 15.5%의 비율로 증가했습니다. 매출은 연평균 2.2%의 비율로 감소해 왔습니다.

주요 정보

-26.3%

수익 성장률

-13.7%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	-2.2%
자기자본 수익률	-561.3%
순이익	-267.0%
최근 수익 업데이트	31 Mar 2024

최근 과거 실적 업데이트

Recent updates

Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now

May 02

Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop

Apr 20

Travere Therapeutics: Restructuring Away From Disaster

Jan 30

Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Jan 22

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too

Dec 18

New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)

Aug 08

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Jun 09

It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks

May 05

Travere Therapeutics GAAP EPS of -$1.05 misses by $0.14, revenue of $54.2M beats by $4.7M

Aug 04

Travere Theraspeutics a new buy at Canaccord as a 'rare disease powerhouse'

Jul 14

Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?

Jun 19

Travere Therapeutics: Strong Sell, Ticking Time Bomb, We Are Passing

Apr 11

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Feb 07

Travere Therapeutics: Tarpeyo's Approval Is Good News

Jan 31

Does Travere Therapeutics (NASDAQ:TVTX) Have A Healthy Balance Sheet?

Oct 07

Regulatory Uncertainty Holding Travere Therapeutics Down Despite PROTECT Study Success

Aug 30

Travere: Setback Presents Cautious Opportunity

Jul 18

Does Travere Therapeutics (NASDAQ:TVTX) Have A Healthy Balance Sheet?

Jul 09

수익 및 비용 분석

Travere Therapeutics 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqGM:TVTX 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Mar 24	156	-416	264	65
31 Dec 23	145	-376	266	0
30 Sep 23	232	-320	282	0
30 Jun 23	223	-315	266	0
31 Mar 23	92	-352	217	0
31 Dec 22	109	-331	198	0
30 Sep 22	137	-297	183	0
30 Jun 22	178	-249	166	0
31 Mar 22	229	-202	160	0
31 Dec 21	132	-217	126	0
30 Sep 21	221	-250	144	-93
30 Jun 21	204	-237	139	-61
31 Mar 21	198	-224	139	-30
31 Dec 20	198	-169	136	0
30 Sep 20	194	-78	128	130
30 Jun 20	187	-92	125	131
31 Mar 20	184	-105	129	138
31 Dec 19	175	-146	129	0
30 Sep 19	172	-124	127	137
30 Jun 19	169	-142	124	136
31 Mar 19	165	-125	110	133
31 Dec 18	164	-103	104	124
30 Sep 18	163	-113	104	111
30 Jun 18	162	-76	101	97
31 Mar 18	160	-67	105	82
31 Dec 17	155	-60	101	78
30 Sep 17	150	-51	101	79
30 Jun 17	144	-70	102	79
31 Mar 17	138	-70	96	77
31 Dec 16	134	-48	92	71
30 Sep 16	127	-42	88	66
30 Jun 16	121	101	87	62
31 Mar 16	112	89	84	55
31 Dec 15	100	117	80	50
30 Sep 15	84	91	69	50
30 Jun 15	64	-33	64	48
31 Mar 15	46	4	53	51
31 Dec 14	28	-111	59	48
30 Sep 14	14	-95	49	38
30 Jun 14	6	-89	36	27
31 Mar 14	0	-105	31	14
31 Dec 13	0	-35	18	7

양질의 수익: TVTX 은(는) 현재 수익성이 없습니다.

이익 마진 증가: TVTX 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: TVTX 은(는) 수익성이 없으며 지난 5년 동안 연간 26.3% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 TVTX 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: TVTX 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -14.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: TVTX 현재 수익성이 없기 때문에 마이너스 자본 수익률( -561.25% )을 갖습니다.

Travere Therapeutics 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Travere Therapeutics, Inc. to Report Q1, 2024 Results on May 06, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Travere Therapeutics, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Travere Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Recent updates

Forecast to breakeven in 2026

Consensus EPS estimates fall by 13%, revenue upgraded

New minor risk - Profitability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2026

Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now

Travere Therapeutics, Inc. to Report Q1, 2024 Results on May 06, 2024

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop

Travere Therapeutics to Present Abstracts on Filspari® (Sparsentan) in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association

Travere Therapeutics, Inc., Annual General Meeting, May 08, 2024

Travere Therapeutics, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration Seeking Full Approval of FILSPARI (Sparsentan) for Treatment of IgA Nephropathy

Travere Therapeutics, Inc. and Csl Vifor Announce Sparsentan Receives Positive Chmp Opinion for the Treatment of Iga Nephropathy

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates upgraded to US$1.86 loss

Travere Therapeutics, Inc. to Report Q4, 2023 Results on Feb 15, 2024

President recently sold US$78k worth of stock

President notifies of intention to sell stock

Travere Therapeutics: Restructuring Away From Disaster

Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Travere Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too

Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)

Consensus EPS estimates fall by 35%

Travere Therapeutics, Inc. Completes Successful Pre-NDA Meeting for FILSPARI in IgAN

Consensus EPS estimates upgraded to US$1.55 loss

Consensus revenue estimates decrease by 16%, EPS upgraded

New major risk - Share price stability

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Travere Therapeutics, Inc. Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and Fs Published in the Lancet and the NEJM Respectively and Presented At the American Society of Nephrology Kidney Week 2023

Travere Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Travere Therapeutics Announces Confirmatory Data from the Phase 3 Protect Study of Filspari Demonstrating Long-Term Kidney Function Preservation in Iga Nephropathy; Narrowly Missing Egfr Total Slope Endpoint Versus Active Control, Irbesartan

Price target decreased by 17% to US$22.40

Mirum Pharmaceuticals, Inc. (NasdaqGM:MIRM) completed the acquisition of Bile Acid Product Portfolio from Travere Therapeutics, Inc. (NasdaqGM:TVTX).

Mirum Pharmaceuticals, Inc. (NasdaqGM:MIRM) completed the acquisition of Bile Acid Product Portfolio from Travere Therapeutics, Inc. (NasdaqGM:TVTX).

Consensus revenue estimates increase by 10%

New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Travere Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Travere Therapeutics, Inc. Announces Positive Topline Results from Cohort 6 in the Phase 1/2 Compose Study of Pegtibatinase in Classical Homocystinuria

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks

Price target decreased by 17% to US$29.33

Insufficient new directors

Consensus EPS estimates fall by 16%

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target increased by 7.2% to US$35.83

Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI(sparsentan), the First and Only Non-Immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

Travere Therapeutics, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

President notifies of intention to sell stock

Travere Therapeutics, Inc. Provides Financial Guidance for the Fourth Quarter and for the Fiscal Year 2022

President notifies of intention to sell stock

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Travere Therapeutics, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Price target decreased to US$33.90

Travere Therapeutics Provides Regulatory Update on Its Sparsentan Program for Iga Nephropathy

Travere Therapeutics' FDA target action date for nephropathy treatment extended

Chief Commercial Officer recently sold US$78k worth of stock

Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?

Travere Therapeutics: Changes In The Risk-Reward Assessment

Travere Therapeutics, Inc. and Csl Vifor Announce Ema Has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of Iga Nephropathy

Travere, CSL kidney disease drug sparsentan gets review in EU

Travere Therapeutics, Inc. Announces Executive Changes

Price target decreased to US$37.33

Second quarter 2022 earnings released: US$1.05 loss per share (vs US$0.64 loss in 2Q 2021)

Travere Therapeutics Provides Regulatory Updates on its Development Programs

Travere Therapeutics GAAP EPS of -$1.05 misses by $0.14, revenue of $54.2M beats by $4.7M